Navigation Links
New England Biolabs opens seventh subsidiary in Singapore
Date:3/21/2013

IPSWICH, Mass., March 21, 2013 /PRNewswire/ -- New England Biolabs (NEB), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Pte. Ltd., in Singapore.

(Logo:  http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

"The Singapore facility will provide the vibrant local scientific research community with more efficient access to the latest NEB products, technical support in the local time zone and languages, as well as OEM partnership opportunities," says Sue Yap , General Manager for the Singapore office.

Singapore, recently cited by Scientific American as the world's third most innovative country in biotech, is home to more than 5,000 life science researchers, numerous start-ups, and facilities for many of the largest pharmaceutical companies. Its significance to the biological sciences was reflected this past January, when the country hosted the inaugural Global Young Scientists Summit, featuring 12 Nobel Prize Laureates. Among these was the Chief Scientific Officer of NEB, Sir Richard Roberts , who conducted a seminar to inaugurate the opening of the NEB office.

"Singapore has a world class reputation in the life sciences. This new office will allow us to offer even greater personalized service and, when appropriate, to explore higher levels of collaboration, especially with the startup biotech companies now multiplying in Singapore," says Roberts.

NEB also maintains subsidiary offices in Canada, China, France, Germany, Japan, and the United Kingdom.

For more information, send e-mail to sales.sg@neb.com or telephone +65 67760903.

About New England Biolabs

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, library preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
2. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
3. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
4. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
5. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
6. New England Cord Blood Bank chooses Sepax 2 from Biosafe as their Cord Blood Processing Platform
7. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
8. New England Biolabs New Website Adds Technical Information, Easy Ordering, and Better Search
9. Store-A-Tooth™ Stem Cell Banking Announces Appointment of Dedicated Sales Representative in New England
10. Quadrant Engineering Plastic Products Appoints a New England Territorial Manager and Production Supervisor
11. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):